D. J. Pullen
University of Mississippi Medical Center
5 Papers
101 Citations
D. J. Pullen is an academic researcher from University of Mississippi Medical Center. The author has contributed to research in topics: Acute lymphocytic leukemia & Lymphoblast. The author has an hindex of 5, co-authored 5 publications. Previous affiliations of D. J. Pullen include Pediatric Oncology Group.
Chat about Author
Papers
Accumulation of Methotrexate Polyglutamates, Ploidy and Trisomies of Both Chromosomes 4 and 10 in Lymphoblasts from Children with B-Progenitor Cell Acute Lymphoblastic Leukemia: a Pediatric Oncology Group Study
V M Whitehead,M J Vuchich,Linda D. Cooley,Stephen J. Lauer,Donald H. Mahoney,Jonathan J. Shuster,C Payment,P. A. Koch,J. J. Akabutu,T Bowen,Barton A. Kamen,Yaddanapudi Ravindranath,A. Emami,A. T. Look,G. P. Beardsley,D. J. Pullen,Bruce M. Camitta +16 more
TL;DR: Improved response to multi-agent chemotherapy conferred by the presence of trisomies of both chromosomes 4 and 10 in such patients may be due to increased sensitivity of their lymphoblasts to one or more anti-leukemic agents in addition to methotrexate.
38
Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
V.M. Whitehead,V.M. Whitehead,J J Shuster,M J Vuchich,Donald H. Mahoney,Stephen J. Lauer,C Payment,P. A. Koch,Linda D. Cooley,A T Look,D. J. Pullen,Bruce M. Camitta +11 more
TL;DR: The notion that higher dose MTX therapy has contributed to increased cure, particularly for patients whose lymphoblasts accumulate the drug less well, is supported.
31
The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
V M Whitehead,C Payment,Linda D. Cooley,Stephen J. Lauer,Donald H. Mahoney,J J Shuster,M J Vuchich,Mark L. Bernstein,A T Look,D. J. Pullen,Bruce M. Camitta +10 more
TL;DR: When planning reduction of therapy for either of the two excellent outcome categories of hyperdiploid or TEL-AML1 BpALL, one should consider the difference between these two subgroups in the ability of lymphoblasts to accumulate methotrexate polyglutamates (MTXPGs).
27
Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: experience of the Pediatric Oncology Group.
Michael J. Borowitz,Michael J. Borowitz,Andrew J. Carroll,Andrew J. Carroll,J J Shuster,J J Shuster,A. T. Look,Frederick G. Behm,D. J. Pullen,D. J. Pullen,Vita J. Land,Vita J. Land,P. Steuber,P. Steuber,William M. Crist +14 more
TL;DR: For more than a decade, the Pediatric Oncology Group (POG) has been engaged in a series of studies of acute lymphocytic leukemia in childhood in which advances in therapeutic approaches have been undertaken in conjunction with biologic studies of the properties of leukemic cells.
13
Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study
TL;DR: It is concluded that immunophenotyping is highly predictive of the TEL rearrangement, and prescreening by phenotyping would eliminate the need for molecular testing on 57 patients and only two or three of an expected 24 patients with the Tel rearrangements would not be detected.